Indiana University Launches Study to Analyze Tecentriq Resistance in Small Cell Lung Cancer Using Rapid Autopsy-Based Tumor Collection
A New Approach to Overcoming Treatment Resistance in Small Cell Lung Cancer
Small Cell Lung Cancer (SCLC) is a highly aggressive cancer characterized by rapid progression and the swift development of drug resistance after initial treatment. Researchers at the Indiana University Simon Comprehensive Cancer Center have initiated a clinical observational study to establish a rapid autopsy protocol for collecting metastatic tissue within 10 hours of patient death. This aims to overcome the challenges of tracking multiple metastases to various organs and tumor heterogeneity, which are difficult to assess with conventional pre-mortem biopsies. By systematically collecting post-mortem tissue from actual patients, this study will provide a unique opportunity to identify the molecular evolutionary pathways that cancer cells select to survive after drug exposure.
Building a Preclinical Platform Through the Acquisition of High-Quality Biospecimens
The SCLC patient tissue collected from metastatic sites, including the lungs, liver, and skin, will undergo comprehensive molecular analysis, such as Whole Exome Sequencing (WES) and RNA sequencing. Furthermore, a key objective is to establish patient-derived xenograft (PDX) models and ex vivo cell lines, rather than simply analyzing the data. The combination of this genomic data and in vivo models will create a preclinical evaluation platform that accurately replicates the tumor characteristics of actual patients, enabling the prediction of the responsiveness of new drug candidates. Ultimately, this is expected to reduce the uncertainty in clinical trial design and expand the infrastructure for personalized precision medicine.
Accelerating Resistance Analysis of Immunotherapies and Novel Targeted Therapies
The current standard of care for SCLC involves a combination of PD-L1-targeting immune checkpoint inhibitors, such as atezolizumab (Tecentriq) and durvalumab (Imfinzi), and chemotherapy. Second-line treatments include lurbinectedin (Zepzelca) and talazatamab (Imdelltra), which recently received accelerated FDA approval. However, overcoming resistance remains a major challenge. By analyzing the mechanisms of tumor resistance in patients treated with standard and novel therapies through rapid autopsy, researchers can clearly identify the genetic mutations and microenvironmental changes that contribute to resistance. This will provide critical data to accelerate the development of competitive follow-up pipelines and re-establish combination therapy strategies for existing drugs.
The Business Value of Translational Research Data in a Large Market
The global SCLC treatment market is projected to grow rapidly from approximately $8.14 billion in 2026 to $22.86 billion in 2035, with an annual growth rate of 12.17%. Researchers and the pharmaceutical and biotechnology industries are seeking translational research data that aligns with the clinical setting to reduce the failure rate of new drug development. The protocol development led by Indiana University can be expanded into a multi-institutional study to establish global standards for standardized cancer biobanks. This will ultimately reduce the target discovery costs for anticancer drug developers, support efficient biomarker validation, and drive value across the industry.
This study provides a translational research platform for overcoming drug resistance in the global SCLC treatment market, which is projected to grow from approximately $8.14 billion in 2026 to $22.86 billion in 2035, with an annual growth rate of 12.17%. Although classified as a non-interventional observational study, the study's focus on obtaining actual post-mortem tumor tissue from patients who have relapsed after treatment with first-line immune checkpoint inhibitors, such as Roche's atezolizumab and AstraZeneca's durvalumab, sets it apart. Researchers will be able to obtain key comparative data to analyze the mechanisms of resistance to second-line treatments, such as Jazz Pharmaceuticals' lurbinectedin and Amgen's talazatamab, through genomic analysis of samples collected within 10 hours of death. Industry professionals will benefit from the ability to pre-validate the efficacy of new drug candidates in the preclinical stage using patient-derived xenograft (PDX) models, significantly reducing the time and cost of clinical development. In the short term, the study will evaluate the clinical applicability of a standard autopsy protocol, and in the long term, it is expected to establish itself as a bio-infrastructure that will facilitate the development of next-generation targeted immunotherapies and companion diagnostic biomarkers by making the accumulated genomic library available.
Source: ClinicalTrials.gov (api_ct)